Private Asset Management Inc. trimmed its holdings in shares of UnitedHealth Group Incorporated (NYSE:UNH) by 10.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,120 shares of the healthcare conglomerate’s stock after selling 133 shares during the quarter. Private Asset Management Inc.’s holdings in UnitedHealth Group were worth $417,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also bought and sold shares of the stock. Norges Bank purchased a new position in shares of UnitedHealth Group in the 4th quarter worth about $3,397,896,000. Viking Global Investors LP purchased a new position in shares of UnitedHealth Group in the 4th quarter worth about $979,682,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of UnitedHealth Group by 5.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 38,003,233 shares of the healthcare conglomerate’s stock worth $13,318,678,000 after purchasing an additional 1,881,407 shares in the last quarter. Morgan Stanley boosted its holdings in shares of UnitedHealth Group by 14.1% in the 4th quarter. Morgan Stanley now owns 7,989,764 shares of the healthcare conglomerate’s stock worth $2,801,850,000 after purchasing an additional 986,472 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in shares of UnitedHealth Group by 5.2% in the 4th quarter. Alliancebernstein L.P. now owns 11,485,225 shares of the healthcare conglomerate’s stock worth $4,027,639,000 after purchasing an additional 569,142 shares in the last quarter. Institutional investors and hedge funds own 86.03% of the company’s stock.
UNH stock opened at $365.64 on Thursday. UnitedHealth Group Incorporated has a fifty-two week low of $246.26 and a fifty-two week high of $380.50. The business’s 50 day moving average price is $351.44 and its two-hundred day moving average price is $339.34. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.82 and a current ratio of 0.82. The company has a market capitalization of $345.65 billion, a price-to-earnings ratio of 21.00, a price-to-earnings-growth ratio of 1.55 and a beta of 0.74.
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 23rd. Investors of record on Monday, March 15th were paid a $1.25 dividend. The ex-dividend date of this dividend was Friday, March 12th. This represents a $5.00 annualized dividend and a dividend yield of 1.37%. UnitedHealth Group’s payout ratio is currently 33.09%.
In other UnitedHealth Group news, Director Richard T. Burke sold 4,000 shares of the stock in a transaction on Monday, March 15th. The stock was sold at an average price of $353.32, for a total transaction of $1,413,280.00. Following the sale, the director now directly owns 153,953 shares in the company, valued at approximately $54,394,673.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Thomas E. Roos sold 619 shares of the stock in a transaction on Tuesday, February 9th. The shares were sold at an average price of $323.90, for a total value of $200,494.10. Following the sale, the chief accounting officer now owns 31,908 shares in the company, valued at $10,335,001.20. The disclosure for this sale can be found here. Insiders sold a total of 9,619 shares of company stock worth $3,292,774 in the last 90 days. 0.80% of the stock is currently owned by company insiders.
UNH has been the subject of a number of recent research reports. Barclays reissued a “buy” rating and issued a $405.00 target price on shares of UnitedHealth Group in a research note on Sunday, January 17th. Truist boosted their target price on UnitedHealth Group from $400.00 to $420.00 in a research note on Tuesday, January 5th. Deutsche Bank Aktiengesellschaft boosted their target price on UnitedHealth Group from $404.00 to $409.00 and gave the company a “buy” rating in a research note on Thursday, January 21st. SVB Leerink boosted their target price on UnitedHealth Group from $378.00 to $390.00 and gave the company an “outperform” rating in a research note on Monday, December 14th. Finally, Bank of America reaffirmed a “buy” rating and set a $415.00 price target on shares of UnitedHealth Group in a research report on Thursday, January 21st. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $387.82.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, Children's Health Insurance Program, and health care programs; medical and dental benefits; and health care delivery.
See Also: What is meant by a buy rating?
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.